MA30335B1 - Compositions antibiotiques a liberation modifiee et leur procede de production - Google Patents

Compositions antibiotiques a liberation modifiee et leur procede de production

Info

Publication number
MA30335B1
MA30335B1 MA31291A MA31291A MA30335B1 MA 30335 B1 MA30335 B1 MA 30335B1 MA 31291 A MA31291 A MA 31291A MA 31291 A MA31291 A MA 31291A MA 30335 B1 MA30335 B1 MA 30335B1
Authority
MA
Morocco
Prior art keywords
antibiotic
dosage form
release
hours
pharmaceutically acceptable
Prior art date
Application number
MA31291A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Munish Talwar
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA30335B1 publication Critical patent/MA30335B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à libération modifiée innovantes qui comprennent au moins un antibiotique, de préférence de l'amoxicilline ou ses sels, esters, polymorphes, isomères, promédicaments, solvates, hydrates ou dérivés pharmaceutiquement acceptables, seul ou en combinaison avec un ou des autres antibiotiques en tant que matière active, avec au moins un agent modificateur de la libération destiné à réguler la libération du bêta lactame antibiotique, facultativement avec un ou plusieurs autres excipients pharmaceutiquement acceptables, la forme pharmaceutique assurant une libération ne dépassant pas environ 60 % de l'antibiotique en environ 30 minutes et n'étant pas inférieure à environ 70 % de l'antibiotique après 8 heures dans une étude de dissolution in vitro ou lors d'un essai in vivo. L'invention concerne en outre des compositions qui, lors d'essais sur un groupe d'humains en bonne santé, fournit une concentration plasmatique maximale moyenne (Cmax) au moins environ 0,5 heure après l'administration de la forme pharmaceutique. La présente invention concerne également des procédés de préparation d'une telle forme pharmaceutique et des procédés d'utilisation d'une telle forme pharmaceutique.
MA31291A 2006-03-24 2008-10-15 Compositions antibiotiques a liberation modifiee et leur procede de production MA30335B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN824DE2006 2006-03-24

Publications (1)

Publication Number Publication Date
MA30335B1 true MA30335B1 (fr) 2009-04-01

Family

ID=38540834

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31291A MA30335B1 (fr) 2006-03-24 2008-10-15 Compositions antibiotiques a liberation modifiee et leur procede de production

Country Status (16)

Country Link
US (1) US20090111788A1 (fr)
EP (1) EP2001465A1 (fr)
JP (1) JP2009530367A (fr)
KR (1) KR20090006123A (fr)
CN (1) CN101410109A (fr)
AU (1) AU2007230546A1 (fr)
BR (1) BRPI0709179A2 (fr)
CA (1) CA2644911A1 (fr)
CR (1) CR10388A (fr)
EA (1) EA200870368A1 (fr)
MA (1) MA30335B1 (fr)
MX (1) MX2008012260A (fr)
RS (1) RS20080430A (fr)
TN (1) TNSN08348A1 (fr)
WO (1) WO2007110875A1 (fr)
ZA (1) ZA200807943B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214680A4 (fr) * 2007-10-26 2010-12-29 Rexahn Pharmaceuticals Inc Formulation pharmaceutique de l'acide clavulanique
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
CA2758029A1 (fr) * 2009-04-29 2011-11-04 Rexahn Pharmaceuticals, Inc. Formulation de clavulanate pour une neuroprotection et un traitement de troubles neurodegeneratifs
WO2011086575A2 (fr) * 2010-01-13 2011-07-21 Toyochem Laboratories Composition pharmaceutique destinée au traitement d'infections du tractus respiratoire
EP2575777A1 (fr) * 2010-06-03 2013-04-10 Mahmut Bilgic Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique
CN102861015B (zh) * 2011-07-05 2015-07-08 北京乐维生物技术有限公司 一种稳定的阿莫西林克拉维酸钾缓释制剂及其制备工艺
CN104582692A (zh) * 2012-08-28 2015-04-29 中化帝斯曼制药有限公司荷兰公司 包含抗生素和β-内酰胺酶抑制剂的组合物，其中抗生素和β-内酰胺酶抑制剂中的至少一种是迷你片剂的形式
US9254261B2 (en) * 2014-03-03 2016-02-09 Sandoz Ag Stable quick dissolving dosage form comprising amoxicillin and clavulanic acid
EP3125873B1 (fr) 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Comprimés monolithiques à libération modifiée se désintégrant, contenant des granules à libération prolongée quadri-couches
US10335374B2 (en) * 2014-12-04 2019-07-02 University System of Georgia, Valdosta State University Tablet composition for anti-tuberculosis antibiotics
MX369634B (es) * 2015-02-20 2019-11-14 Cytec Ind Inc Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso.
JP7370125B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP7370124B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
CN113116860B (zh) * 2021-04-22 2022-11-25 海南通用三洋药业有限公司 一种阿莫西林胶囊及其制备方法
CN113398069A (zh) * 2021-07-10 2021-09-17 四川成康动物药业有限公司 兽用阿莫西林与磺胺嘧啶钠混悬注射液及制备方法和装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201930D0 (sv) * 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
EP1330236A2 (fr) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles

Also Published As

Publication number Publication date
WO2007110875A1 (fr) 2007-10-04
CA2644911A1 (fr) 2007-10-04
TNSN08348A1 (en) 2009-12-29
CN101410109A (zh) 2009-04-15
RS20080430A (sr) 2009-05-06
KR20090006123A (ko) 2009-01-14
ZA200807943B (en) 2009-11-25
EP2001465A1 (fr) 2008-12-17
CR10388A (es) 2009-01-19
BRPI0709179A2 (pt) 2011-06-28
MX2008012260A (es) 2008-10-07
AU2007230546A1 (en) 2007-10-04
EA200870368A1 (ru) 2009-04-28
JP2009530367A (ja) 2009-08-27
US20090111788A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
MA30335B1 (fr) Compositions antibiotiques a liberation modifiee et leur procede de production
JP6720301B2 (ja) 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をｉｎ ｖｉｖｏで増強する方法
EP3288553B1 (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
Magariños et al. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress
Horres et al. The roles of neutral sphingomyelinases in neurological pathologies
Lanznaster et al. Guanosine prevents anhedonic-like behavior and impairment in hippocampal glutamate transport following amyloid-β1–40 administration in mice
MA26960A1 (fr) Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
JP2010505958A (ja) 神経防護作用組成物および方法
EA200500080A1 (ru) Дозированная форма прамипексола, принимаемая один раз в день
CN105142632A (zh) 通过投予尿石素或其前体增强自噬或增加寿命
CA2611201A1 (fr) Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
US20220249483A1 (en) Compositions and methods for treatment of fragile x syndrome
US20210393645A1 (en) Treatment for progressive multiple sclerosis
EP2725901A1 (fr) Compositions, méthodes et nécessaires pour traiter la leucémie
Kiyofuji et al. A natural compound macelignan protects midbrain dopaminergic neurons from inflammatory degeneration via microglial arginase-1 expression
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
CA3073801C (fr) Compositions et methodes pour soulager la douleur
US20170304251A1 (en) Avocado-derived lipids for use in treating leukemia
US8338410B2 (en) Neuroprotective compounds and pharmaceutical compositions comprising them
FR2805462B1 (fr) Nouvelle forme galenique orale a liberation prolongee de la molsidomine
Miao et al. Curcumin Ameliorates Chronic Mild Stress-Induced Depressive-Like Behavior via HMGB1/TLR4/NF-κB Signaling Pathway
NZ619377B2 (en) Compositions, methods and kits for treating leukemia